GlassScriptPhysician profile
Benjamin Carpenter
NPI 1124312822
$2,234.66
in general payments reported to CMS, 2019-2025
28 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $160 · 2021: $300 · 2022: $483 · 2023: $975 · 2024: $41.72 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.25 | 2019-2024 | Botox, Avycaz, Lupron Depot |
| Astellas Pharma US INC | $274.43 | 2019-2023 | Myrbetriq |
| Allergan, INC. | $219.32 | 2020-2022 | |
| Intuitive Surgical, INC. | $122.93 | 2020-2023 | Da Vinci Surgical System |
| Progenics Pharmaceuticals, INC. | $118.86 | 2023 | Pylarify |
| Procept Biorobotics Corporation | $114.82 | 2025 | |
| Amgen INC. | $86.89 | 2020-2021 | |
| Pfizer INC. | $62.47 | 2023 | |
| Boston Scientific Corporation | $61.46 | 2022-2025 | Ams 700, Rezum Generator |
| Bayer Healthcare Pharmaceuticals INC. | $58.00 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $55.23 | 2023 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $44.39 | 2022 | |
| Alnylam Pharmaceuticals INC. | $43.52 | 2021 | |
| Travere Therapeutics, INC. | $43.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $39.61 | 2022-2023 | Keytruda, Welireg, Lynparza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $34.49 | 2023 | Jelmyto |
| Angiodynamics, INC. | $33.31 | 2023 | Nanoknife |
| Stryker Corporation | $31.13 | 2022 | |
| 180 Medical, INC. | $25.20 | 2024 | |
| Myriad Genetic Laboratories, INC. | $24.19 | 2021 | |
| Hollister Incorporated | $24.13 | 2022 | |
| Urovant Sciences INC | $22.84 | 2022 | |
| Janssen Biotech, INC. | $22.66 | 2023 | Erleada |
| Astrazeneca Pharmaceuticals LP | $18.11 | 2023 | Lynparza |
| Endo Pharmaceuticals INC. | $18.00 | 2019 | |
| Telix Pharmaceuticals | $17.13 | 2023 | Illuccix |
| Olympus America INC. | $12.42 | 2021 | |
| Dendreon Pharmaceuticals LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.